Sarah Ronnebaum, Abdalla Aly, Dipen Patel, Fernando Benavente, Juan-David Rueda
{"title":"肝细胞癌推荐系统治疗试验的系统文献综述。","authors":"Sarah Ronnebaum, Abdalla Aly, Dipen Patel, Fernando Benavente, Juan-David Rueda","doi":"10.2217/hep-2021-0003","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To identify and evaluate the similarity of all trials assessing recommended treatments for advanced hepatocellular carcinoma.</p><p><strong>Materials & methods: </strong>Single arm and randomized trials from any phase and published any time up to February 2021 were systematically searched.</p><p><strong>Results: </strong>From 5677 records reviewed, 50 trials were included in the review, and 24 for assessed for similarity. In the first-line (1L) setting, several trials assessing sorafenib were noted for enrolling patients with more severe disease and/or performance status than other 1L trials; trials within the second-line (2L) setting were generally similar. Median survival was <2 years in all trial arms.</p><p><strong>Conclusions: </strong>Trials assessing recommended treatments are largely similar and appropriate for quantitative comparisons of several efficacy and safety outcomes.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"9 1","pages":"HEP41"},"PeriodicalIF":1.2000,"publicationDate":"2021-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5d/7b/hep-09-41.PMC8577513.pdf","citationCount":"0","resultStr":"{\"title\":\"Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma.\",\"authors\":\"Sarah Ronnebaum, Abdalla Aly, Dipen Patel, Fernando Benavente, Juan-David Rueda\",\"doi\":\"10.2217/hep-2021-0003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>To identify and evaluate the similarity of all trials assessing recommended treatments for advanced hepatocellular carcinoma.</p><p><strong>Materials & methods: </strong>Single arm and randomized trials from any phase and published any time up to February 2021 were systematically searched.</p><p><strong>Results: </strong>From 5677 records reviewed, 50 trials were included in the review, and 24 for assessed for similarity. In the first-line (1L) setting, several trials assessing sorafenib were noted for enrolling patients with more severe disease and/or performance status than other 1L trials; trials within the second-line (2L) setting were generally similar. Median survival was <2 years in all trial arms.</p><p><strong>Conclusions: </strong>Trials assessing recommended treatments are largely similar and appropriate for quantitative comparisons of several efficacy and safety outcomes.</p>\",\"PeriodicalId\":44854,\"journal\":{\"name\":\"Hepatic Oncology\",\"volume\":\"9 1\",\"pages\":\"HEP41\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2021-08-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5d/7b/hep-09-41.PMC8577513.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/hep-2021-0003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2021-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/3/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma.
Aim: To identify and evaluate the similarity of all trials assessing recommended treatments for advanced hepatocellular carcinoma.
Materials & methods: Single arm and randomized trials from any phase and published any time up to February 2021 were systematically searched.
Results: From 5677 records reviewed, 50 trials were included in the review, and 24 for assessed for similarity. In the first-line (1L) setting, several trials assessing sorafenib were noted for enrolling patients with more severe disease and/or performance status than other 1L trials; trials within the second-line (2L) setting were generally similar. Median survival was <2 years in all trial arms.
Conclusions: Trials assessing recommended treatments are largely similar and appropriate for quantitative comparisons of several efficacy and safety outcomes.
期刊介绍：
Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
